Tuesday 30 March 2021
In a historic move in the global fight against the COVID-19 pandemic, the United Arab Emirates has begun the manufacturing of a COVID-19 vaccine in the country.
The vaccine, called Hayat-Vax [Hayat means 'Life' in Arabic], is the first indigenous COVID-19 vaccine in the region that will be manufactured by a newly created joint venture between Sinopharm CNBG, one of the largest pharmaceutical companies in the world that has supplied over 100 million doses of the COVID-19 vaccine globally, and G42, the leading technology company based in Abu Dhabi.
The partners also launched a purpose-built research and development hub for life sciences, biotechnology, and vaccine production – the first of its kind in the Arab World – that is being set up in KIZAD, the integrated trade, logistics, and industrial hub in Abu Dhabi.
Last year, G42 and Sinopharm CNBG successfully collaborated on conducting 4Humanity, the world’s first phase III clinical trial of inactivated vaccines across the Pan Arab region with over 43,000 volunteers participating from over 125 nationalities.
The new vaccine plant in KIZAD will become operational this year and over its phased development will have a production capacity of 200 million doses per annum across three filling lines and five automated packaging lines. The JV is already producing Hayat-Vax with its partner Julphar in the UAE with an initial capacity of 2 million doses per month.
Hayat-Vax is the same Sinopharm BiBP inactivated vaccine that was officially registered by the UAE Ministry of Health and Prevention (MOHAP) on 9 December 2020 and subsequently in China by the Chinese Center for Drug Evaluation (CDE) on 30 December 2020 following the updated Sinopharm interim results submitted in China showing 79.34% efficacy.
The UAE has vaccinated over 52% of the country’s population. This first-ever ‘Made in UAE’ vaccine will turbocharge this program across 205 medical centers nationally.